Methodological issues of clinical research with EGFR inhibitors

Current Cancer Therapy Reviews

Volumn 3, Issue 4, 2007, Pages 292-302

  Morabito, Alessandro ^a   Piccirillo, Maria Carmela ^a   Monaco, Katia ^a   Falasconi, Fabiano ^a   Normanno, Nicola ^a   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cetuximab; EGFR; Erlotinib; Gefitinib; Lapatinib; Panitumumab

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PLACEBO; PLATINUM COMPLEX; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALUTUMUMAB;

BREAST CANCER; CARCINOGENESIS; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; INJECTION SITE REACTION; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; METHODOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 36949005161     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339407782497031     Document Type: Review

References (95)

1. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs fbr cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19: 265-272.
2. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Ann Oncol 1998; 9: 1047-1052.
3. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925-937.
4. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a pratical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
5. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs 2000; 18: 7-16.
6. Parulekar WR, Eisenhauer EA. Novel endpoints and design of early clinical trials. Ann Oncol 2002; 13 (suppl.4): 139-143.
7. Korn EL. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Natl Cancer Inst 2004; 96: 977-978.
8. Hidalgo M, Messersmith W. Pharmacodynamic studies in drug development. Educational Book of American Society of Clinical Oncology 2004; 160-163.
9. Morabito A, Di Maio M, De Maio E, Normanno N, Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand? Ann Oncol 2006; 17: 28-31.
10. Mick R, Crowley JJ, Carrol RJ, et al. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000; 21: 343-359.
11. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20: 4478-4484.
12. Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 2005; 22: 5094-5098,
13. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 2005; 23: 4450-4457.
14. Perrone F, Di Maio M, De Maio E, et al. Statistical design in phase II clinical trials and their application in breast cancer. Lancet Oncol 2003; 4: 305-311.
15. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19: 265-272.
16. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20: 2495-2499.
17. Wells A. EGF receptors. Int J Biochem Cell Biol 1999; 31: 637-643.
18. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: 32S-40S.
19. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18: 54S-59S.
20. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754.
21. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in Non-small-cell lung cancer and other solid turnors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-3825.
22. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302.
23. Albanell J, Rojo E, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
24. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
25. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
26. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor recetor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
27. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
28. Giaccone G, Ruiz MG, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12: 6049-6055.
29. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 760-766.
30. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784
31. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
32. Herbst RS, Prager D, Hermann I, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel, chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
33. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007; 25: 1545-1552.
34. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
35. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-484.
36. Piperdi B, Ling YH, Kroog G, et al. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. J Clin Oncol 2004; 22 (14S): 7028 (abstr).
37. Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol 2005; 205: 355-363.
38. Lynch TJ, Bell DW, Sordella R, et al. Activationg mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
39. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
40. Tliatcher N, Chang A, Parikh P, et al. gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
41. Niho S, Ichinose Y, Tamura T, et al. Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 2007; 25: 18S: LBA7509.
42. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
43. Bezjak A, Tu D, Seymour L, et al. Symptoms improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer institute of Canada Clinical Trials Group study BR.21. J Clin Oncol 2006; 24: 3831-3837.
44. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
45. Akita RW, Dugger D, Lewis PG, et al. Effects of the EGFR inhibitor Tarceva on activated ErbB2. Am Assoc Cancer Res 2002; 43: 4973 (abstr.).
46. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005; 16: 538-548.
47. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004; 22: 759-761.
48. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
49. Normanno N. Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination? J Clin Oncol 2005; 23: 928-930.
50. Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007; 13: 3413-3422.
51. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
52. Lackey KL. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Topics Med Chem 2006; 6: 435-460.
53. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
54. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-6263.
55. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
56. Burris III HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313.
57. Spector NL, Xia W, Burris III HA. et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinase, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-2512.
58. Burstein H, Storniolo AM, Franco S, et al. A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol 2004; 15 (3S): 1040 (abstr.).
59. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004; 22 (14S): 3006 (abstr.)
60. Schwartz G, Chu QS, Hammond LA, et al. Phase I clinical, biology, and pharmacokinetic study of the combination of GW572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol 2004; 22 (14S): 3070 (abstr.).
61. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
62. Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 2006; 100 (S5): 1 (abstr.).
63. Di Leo A, Gomez H, Aziz Z, et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients. J Clin Oncol 2007; 25 (18S): 1011 (abstr.).
64. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95: 851-867.
65. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with Cisplatin. J Clin Oncol 2000; 18: 904-914.
66. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with eadiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-3243.
67. Tan AR, Moore DF, Hidalgo M, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006; 12: 6517-6522.
68. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7: 1204-1213.
69. Fracasso PM, Burris III H, Arquette MA, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13: 986-993.
70. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
71. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
72. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456.
73. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921.
74. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
75. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
76. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
77. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544.
78. Eng C, Maurel J, Scheithauer W, et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. J Clin Oncol 25; 18S: 2007: 4003 (abst.)
79. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 25; 18S: 2007: 4000 (abst.)
80. Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 9089-9096.
81. Thienelt CD, Bunn Jr PA, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 8786-8793.
82. Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24: 5253-5259.
83. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-2872.
84. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
85. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587.
86. Pfister DG, Bernard Su Y, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-1078.
87. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
88. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
89. Vermorken J, Mesia R, Vega V, et al. Cetuximab extend survival of patients with recurrent or meyastatic SCCHN when added to first line platinum based therapy. Results of a randomized phase III (Extreme) study. J Clin Oncol 2007; 25 (18S): (abstr.).
90. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004; 22: 2610-2616.
91. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 2007; 25: 18S: LBA4509.
92. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human antiepidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21: abstr 35.
93. Weiner LM, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 2005 ASCO Annual Meeting Proceedings; 23(16S): 3059.
94. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003-3015.
95. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.